About Axonics
Axonics is a company based in Irvine (United States) founded in 2013 was acquired by Boston Scientific in January 2024. Axonics has raised $143.47 million across 7 funding rounds from investors including Boston Scientific, SVB and Edmond de Rothschild. Axonics has completed 2 acquisitions, including Bulkamid and Contura. Axonics operates in a competitive market with competitors including Amber Therapeutics, NeuSpera Medical, UroMems, Signum Surgical and Averto Medical, among others.
- Headquarter Irvine, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$143.47 M (USD)
in 7 rounds
-
Latest Funding Round
$20 M (USD), Debt – Conventional
Apr 03, 2018
-
Investors
Boston Scientific
& 10 more
-
Employee Count
Not available
-
Investments & Acquisitions
Bulkamid
& 1 more
-
Acquired by
Boston Scientific
(Jan 08, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Axonics
Unlock access to complete
Unlock access to complete
Funding Insights of Axonics
Axonics has successfully raised a total of $143.47M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $20 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Axonics
Axonics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, SVB and Edmond de Rothschild.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Axonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axonics
Axonics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bulkamid and Contura.
Investment portfolio details for Axonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of the bulking agent for women urinary incontinence
|
Locked | Locked | 2003 | Locked | |
|
Generic drugs and hydrogel products are manufactured by Contura.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Axonics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Axonics
Detailed financials for Axonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axonics Comparisons
Peer comparison for Axonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axonics
Axonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amber Therapeutics, NeuSpera Medical, UroMems, Signum Surgical and Averto Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Bioelectrical therapies for peripheral nervous system disorders are developed.
|
|
| Locked | Locked | Locked |
Miniaturized injectable neuromodulation devices are developed for chronic diseases.
|
|
| Locked | Locked | Locked |
Developer of active implantable devices for urological incontinence
|
|
| Locked | Locked | Locked |
Surgically implanted devices for perianal fistula treatment are provided.
|
|
| Locked | Locked | Locked |
Medical devices for gastrointestinal disease patients are developed.
|
Detailed competitors of Axonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axonics
Complete news archive for Axonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axonics
Axonics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Axonics is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Raymond W Cohen is the current CEO of Axonics.
Axonics is a funded company, having raised a total of $143.47M across 7 funding rounds to date.
Axonics was founded in 2013 in Irvine, United States, within the medical device sector. Implantable neurostimulators are developed using sacral neuromodulation technology to address urinary and bowel dysfunctions. The system features a compact device with a helical-tined lead to minimize migration, implanted in the sacral area, and supported by a tablet-based programmer for clinical adjustments. Operations focus on innovation in neuromodulation for pelvic health management.
Axonics's top competitors include NeuSpera Medical, Amber Therapeutics and UroMems.
Axonics has 11 investors. Key investors include Boston Scientific, SVB, Edmond de Rothschild, Longitude Capital, and Gilde Healthcare.